Clinical Trials Logo

Dyskinesia clinical trials

View clinical trials related to Dyskinesia.

Filter by:

NCT ID: NCT00114595 Completed - Schizophrenia Clinical Trials

Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia

Start date: April 2003
Phase: Phase 4
Study type: Interventional

Tardive dyskinesia is a common complication of conventional antipsychotic treatment in subjects with schizophrenia. This study investigates whether the addition of the omega-3 fatty acid, ethyl-eicosapentaenoic acid (EPA) to usual treatment improves movement disorder in 84 schizophrenia subjects with established tardive dyskinesia. The initial double-blinded, randomised trial duration is 12 weeks, followed by further 46 weeks of open-label treatment.

NCT ID: NCT00105521 Completed - Parkinson's Disease Clinical Trials

Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia

Start date: September 30, 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test multiple doses of sarizotan to establish a dose with maximal safety and efficacy for treating treatment associated dyskinesia in Parkinson's disease participants.

NCT ID: NCT00105508 Completed - Parkinson's Disease Clinical Trials

Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia

Start date: September 30, 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine if Sarizotan HC1 1 mg b.i.d. (taken twice a day) is effective in the treatment of dyskinesia associated with dopaminergic treatment of Parkinson's disease (PD).